SCHEMBL25587239

SCHEMBL25587239

CC(F)(F)Oc1ccc(C(C)(C)C)cn1

nearest known ligand 0.44

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 3/20 0.44
POLB P06746 2/20 0.44
KDM4E B2RXH2 1/20 0.44
TSHR P16473 2/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
HPGD P15428 1/20 0.40
KMT2A Q03164 1/20 0.38
MAPK1 P28482 1/20 0.38
LMNA P02545 1/20 0.37
THRB P10828 1/20 0.36
MAPT P10636 3/20 0.35
L3MBTL1 Q9Y468 2/20 0.35
NPSR1 Q6W5P4 1/20 0.35
MRGPRX4 Q96LA9 1/20 0.35
HTT P42858 1/20 0.33
LIPE Q05469 2/20 0.33
GABRA5 P31644 1/20 0.33
CNR1 P21554 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21671809 0.89 POLB (0.44) RAB9APOLBKDM4ETSHRSMN1; SMN2
SCHEMBL23589790 0.84 RAB9A (0.50) RAB9APOLBKDM4ETSHRSMN1; SMN2
SCHEMBL18737257 0.81 RAB9A (0.44) RAB9APOLBKDM4ETSHRSMN1; SMN2
SCHEMBL12255679 0.78 L3MBTL1 (0.53) RAB9APOLBKDM4ETSHRSMN1; SMN2
SCHEMBL77481 0.78 KDM4E (0.47) RAB9APOLBKDM4ETSHRSMN1; SMN2
SCHEMBL2737128 0.77 TSHR (0.51) RAB9APOLBKDM4ETSHRSMN1; SMN2
SCHEMBL14925205 0.76 KDM4E (0.42) RAB9APOLBKDM4ETSHRSMN1; SMN2
SCHEMBL6370552 0.75 KDM4E (0.40) RAB9APOLBKDM4ETSHRSMN1; SMN2
SCHEMBL12139578 0.74 MAPT (0.49) RAB9APOLBKDM4ETSHRSMN1; SMN2
SCHEMBL17358383 0.74 POLB (0.41) RAB9APOLBKDM4ETSHRSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230278958-A1 TRICYCLIC HETEROCYCLES MERCK PATENT GMBH (DE) 2023-09-07 US disclosed
US-20230174538-A1 Tricyclic heterocycles MERCK PATENT GMBH (DE) 2023-06-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230278958-A1 TRICYCLIC HETEROCYCLES YAP1, TERF2IP, TEAD1 RAB9A 1789/4885POLB 1569/4885KDM4E 2608/4885
US-20230174538-A1 Tricyclic heterocycles YAP1, TEAD1, TERF2IP RAB9A 1456/4885POLB 1991/4885KDM4E 2269/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.